Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings

References

• Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012
   Google Scholar
• Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125–143
   PubMed Web of Science ®Google Scholar
• Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 2007;87:98–102
   PubMed Web of Science ®Google Scholar
• Sigmon SC. Characterizing the emerging population of prescription opioid abusers. Am J Addict 2006;15:208–212
   PubMed Web of Science ®Google Scholar
• Roy E, Arruda N, Bourgois P. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse 2011;46:1142–1150
   PubMed Web of Science ®Google Scholar
• Gombas W, Fischer G, Jagsch R, Eder H, Okamoto I, Schindler S, Muller C, et al. Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence. Eur Addict Res 2000;6:198–204
   Google Scholar
• Centers for Disease Control and Prevention. Hepatitis C information for health professionals. Atlanta, GA; 2013
   Google Scholar
• Belfiori B, Chiodera A, Ciliegi P, Tosti A, Baldelli F, Stagni G, Francisci D. Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study. Eur J Gastroenterol Hepatol 2007;19:731–732
   Google Scholar
• McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005;41:S89–S95
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237–244
   PubMed Web of Science ®Google Scholar
• Sun X, Patnode CD, Williams C, Senger CA, Kapka TJ, Whitlock EP. Interventions to improve patient adherence to hepatitis C treatment: comparative effectiveness. Rockville, MD: Agency for Healthcare Research and Quality; 2012
   Google Scholar
• Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345:211–215
   PubMed Web of Science ®Google Scholar
• Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005;40:S321–S324
   PubMed Web of Science ®Google Scholar
• Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009;49:561–573
   PubMed Web of Science ®Google Scholar
• Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005;40:S336–S338
   Web of Science ®Google Scholar
• Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57:S80–S89
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. NIH Consensus Development Conference Statement: management of hepatitis C: June 10–12, 2002. Hepatology 2002;36:S3–S20
   Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2004
   Google Scholar
• McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4–16
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. The Drug Addiction Treatment Act of 2000 (DATA 2000) n.d. Available at: http://www.buprenorphine.samhsa.gov/ [last accessed 22 Dec 2010]
   Google Scholar
• Kinsman D, Blaser J. Joint principles of a patient-centered medical home released by organizations representing more than 300 000 physicians 2007. Available at: http://www.acponline.org/pressroom/pcmh.htm [last accessed 15 Aug 2012]
   Google Scholar
• Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104:256–265
   PubMed Web of Science ®Google Scholar
• McPherson S, Barbosa-Leiker C, McDonell M, Howell D, Roll J. Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial. Human Psychopharmacol: Clin Experimental 2013;28:506–515
   Google Scholar
• Cacciola JS, Alterman AI, McLellan AT, Lin YT, Lynch KG. Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug Alcohol Depend 2007;87:297–302
   PubMed Web of Science ®Google Scholar
• Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton, FL: Chapman & Hall/CRC; 2003
   Google Scholar
• Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13–22
   Web of Science ®Google Scholar
• Allison PD. Missing data. Thousand Oaks, CA: Sage; 2001
   Google Scholar
• Little RJA. Missing data. In: Everitt BS, Howell DC, eds. Encyclopedia of statistics in behavioral science. Chichester, UK: Wiley; 2005:1234–1238
   Google Scholar
• Carpenter JR, Kenward MG, Vansteelandt S. A comparison of multiple imputation and doubly robust estimation for analyses with missing data. J Royl Statist Soc: A (Statistics in Society) 2006;169:571–584
   Web of Science ®Google Scholar
• Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Meth 2002;7:147–177
   PubMed Web of Science ®Google Scholar
• Schafer JL. Multiple imputation in multivariate problems when the imputation and analysis models differ. Statistica Neerlandica 2003;57:19–35
   Web of Science ®Google Scholar
• Rubin DB. Multiple imputation for nonresponse in surveys. New York, USA: John Wiley & Sons; 1987
   Google Scholar
• Saffier K, Colombo C, Brown D, Mundt MP, Fleming MF. Addiction Severity Index in a chronic pain sample receiving opioid therapy. J Subst Abuse Treat 2007;33:303–311
   PubMed Web of Science ®Google Scholar